

[全部](#)[新闻](#)[图片](#)[视频](#)[购物](#)[更多](#)[设置](#)[工具](#)

找到约 152,000 条结果 (用时 0.53 秒)

Google 学术: Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status

HER2-positive breast cancer: current management of ... - Callahan - 被引用次数: 55

... and leucovorin for metastatic colorectal cancer - Saltz - 被引用次数: 3375

Palliative treatment of metastatic colorectal cancer: ... - Strickler - 被引用次数: 9

Inhibition of EGFR, HER2, and HER3 signalling in patients with ...

www.thelancet.com/journals/langas/article/PIIS2468...1/fulltext - 翻译此页

作者: R Adams - 被引用次数: 1 - 相关文章

2017年12月15日 - Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase a random element of 20%, minimisation by hospital site, site of primary tumour, WHO performance status, 16-week CT scan result, number of metastatic ...

Treatment decisions in metastatic colorectal cancer â€œ Beyond first ...

[www.cancertreatmentreviews.com/article/S0305-7372\(17\)30065-8/pdf](http://www.cancertreatmentreviews.com/article/S0305-7372(17)30065-8/pdf) - 翻译此页

作者: A Vogel - 2017 - 被引用次数: 7 - 相关文章

Article history: Received 16 February 2016. Received in revised form 24 April 2017. Accepted 25 April 2017. Keywords: Metastatic colorectal cancer. Beyond EGFR inhibitors. If mCRC patients with RAS wild-type did not receive an EGFR inhibitor in earlier treatment lines, this option should be introduced

Name of Journal: *World Journal of Clinical Cases*

Manuscript NO: 39289

Manuscript Type: MINIREVIEWS

Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status

Ozkan Kanat, Hulya Ertas, Burcu Caner

Abstract

Human epidermal growth factor receptor 2 (HER2) signaling pathway activation has been identified as a contributor to de novo or acquired resistance to epidermal growth factor receptor (EGFR) inhibitors in a small subset of patients with metastatic colorectal cancer (mCRC). Dual anti-HER2-targeted treatment exhibits strong antitumor activity in preclinical models of HER2-positive mCRC, supporting its testing in clinical trials. The HERACLES trial at four Italian academic cancer centers has confirmed the effectiveness of dual blockage of HER2 with trastuzumab plus

Match Overview

1	Internet 65 words crawled on 05-May-2016 www.pubfacts.com	2%
2	Crossref 60 words Yoshifumi Shimada, Ryoma Yagi, Hitoshi Kameyama, Masayuki Nagahashi et al. "Utility of comprehensive gen ...	2%
3	Crossref 58 words Erika Martinelli, Teresa Troiani, Vincenzo Sforza, Giulia Martini et al. "Sequential HER2 blockade as effective thera	2%
4	Internet 42 words crawled on 11-Oct-2015 www.nature.com	1%
5	Crossref 36 words "Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways", Spr	1%
6	Internet 32 words crawled on 07-Jun-2016 www.ncbi.nlm.nih.gov	1%
7	Crossref 23 words Andrea Sartore-Bianchi, Livio Trusolino, Cosimo Martino, Katia Bencardino et al. "Dual-targeted therapy with trast	1%
8	Internet 22 words crawled on 29-Aug-2017 d-scholarship.pitt.edu	1%
9	Crossref 21 words Jae Ho Jeong, Jihun Kim, Yong Sang Hong, Dallyong Kim et al. "HER2 Amplification and Cetuximab Efficacy in ...	1%
10	Internet 21 words crawled on 17-Jun-2017 media4.asco.org	1%
11	Crossref 16 words Andrea Sartore-Bianchi, Livio Trusolino, Cosimo Martino, Katia Bencardino et al. "Dual-targeted therapy with trast	<1%

找到约 159,000 条结果 (用时 0.51 秒)

Google 学术 : Dual HER2 inhibition strategies in the management of treatment-refractory metastatic colorectal cancer: History and status

... and leucovorin for metastatic colorectal cancer - Saltz - 被引用次数 : 3396

HER2-positive breast cancer: current management of ... - Callahan - 被引用次数 : 56

... : incidence, pathogenesis, diagnosis, and management - Yeh - 被引用次数 : 810

Management of metastatic colorectal cancer patients: guidelines of the ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519792/> - 翻译此页

作者 : L Salvatore - 2017 - 被引用次数 : 1 - 相关文章

2017年4月12日 - Over the past 15 years, the treatment of metastatic colorectal cancer disease history (eg, a previous oxaliplatin-based adjuvant treatment); ... use of HER-inhibitors in HER-2 overexpressed patients with mCRC. ... C, RAS status must be evaluated for the decision of treatment strategy for metastatic disease.

Recent developments in the treatment of metastatic colorectal cancer

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5524248/> - 翻译此页

作者 : JM Loree - 2017 - 被引用次数 : 9 - 相关文章

2017年6月29日 - Colorectal cancer (CRC) is the third leading cause of cancer and cancer-related death. ... Potential treatment options for patients with metastatic colorectal NGS panels can identify biomarkers to guide therapy, such as RAS status, and ... dual BRAF plus MEK inhibition is similarly not substantially active.

Treatment decisions in metastatic colorectal cancer â€œ Beyond first ...

[www.cancertreatmentreviews.com/article/S0305-7372\(17\)30065-8/pdf](http://www.cancertreatmentreviews.com/article/S0305-7372(17)30065-8/pdf) - 翻译此页

作者 : A Vogel - 2017 - 被引用次数 : 9 - 相关文章

Median overall survival (OS) of patients with metastatic colorectal cancer ... tain a good performance status and a significant proportion is motivated to ... irinotecan, and oxaliplatin), plus VEGF inhibitor(s) and – if RAS wild-type – an ... for this strategy is limited. In a phase III study of patients with chemo-refractory mCRC,.

Inhibition of EGFR, HER2, and HER3 signalling in patients with ...

www.thelancet.com/journals/langas/article/PIIS2468...1/fulltext - 翻译此页

作者 : R Adams - 2018 - 被引用次数 : 1 - 相关文章

2017年12月15日 - Publication History However, EGFR remains a valid target in colorectal cancer within ... of patients with metastatic colorectal cancer harbouring HER2-positive KRAS wild-type